Thongprasert,S., Tinmanee,S., & Permsuwan,U. (2015). Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. Wiley-Blackwell.
استشهاد بنمط شيكاغوThongprasert,S., Tinmanee,S, و Permsuwan,U. Cost-utility and Budget Impact Analyses of Gefitinib in Second-line Treatment for Advanced Non-small Cell Lung Cancer From Thai Payer Perspective. Wiley-Blackwell, 2015.
MLA استشهادThongprasert,S., Tinmanee,S, و Permsuwan,U. Cost-utility and Budget Impact Analyses of Gefitinib in Second-line Treatment for Advanced Non-small Cell Lung Cancer From Thai Payer Perspective. Wiley-Blackwell, 2015.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.